Atypical inflammatory kinase IKBKE phosphorylates and inactivates FoxA1 to promote hepatic tumorigenesis
our findings not only reveal FoxA1 as a bona fide substrate and negative nuclear effector of IKBKE in HCC progression, but also highlight a strategy to combat HCC by antagonizing IKBKE.